Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma.

Alessandra Soriani (1) , Cinzia Fionda (1) , Biancamaria Ricci (1) , Maria Luisa Iannitto (1) , Marco Cippitelli (1) , Angela Santoni (1)

1 Department of Molecular Medicine

Malignant cells constitutively express Natural killer group 2, member D (NKG2D) or DNAX Accessory Molecule-1 (DNAM-1) ligands, yet they are often unable to trigger a robust cytotoxic cell response. It may be therapeutically useful to implement strategies aimed at increasing the density of NKG2D and DNAM-1 ligands on the surface of cancer cells, endowing them with the capacity to activate potent antitumor natural killer-cell responses.

Domains: Life Sciences [q-bio]; Immunology; Life Sciences [q-bio]; Cancer

Alessandra Soriani, Cinzia Fionda, Biancamaria Ricci, Maria Luisa Iannitto, Marco Cippitelli, et al.. Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma.. OncoImmunology, 2013, 2 (12), pp.e26663. ⟨10.4161/onci.26663⟩. ⟨pasteur-01054170⟩